Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2021 | Combining a DNA vaccine with pembrolizumab for mCRPC

Douglas G. McNeel • 12 Nov 2021
SITC 2021
Genitourinary Cancer Prostate Cancer Antibodies Pembrolizumab

Douglas G. McNeel, MD, PhD, University of Wisconsin Carbone Cancer Center, University of Wisconsin, Madison, WI, explains the rationale for combining a DNA vaccine with pembrolizumab to treat metastatic castration-resistant prostate cancer (mCRPC). This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

More from Douglas G. McNeel

0:56
Vaccines are a promising direction for prostate cancer immunotherapy
Douglas G. McNeel • 12 Nov 2021
1:26
Impact of CD8+ T cell activation in the presence of TLR agonists
Douglas G. McNeel • 12 Nov 2021
1:32
Combining antigen-specific vaccination and targeted radionuclide therapy in a murine prostate model
Douglas G. McNeel • 12 Nov 2021
1:30
Asessing the pTVG-HP Plasmid DNA vaccine in patients with mCRPC
Douglas G. McNeel • 12 Nov 2021

Related Videos

3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals